Healthcare -
Medical - Healthcare Information Services - NYSE - US
$ 57.36
0.561 %
$ 10.8 B
Market Cap
51.68
P/E
1. INTRINSIC VALUE
Balance Sheet
Doximity, Inc.
| Current Assets | 1.09 B |
| Cash & Short-Term Investments | 916 M |
| Receivables | 128 M |
| Other Current Assets | 44.6 M |
| Non-Current Assets | 176 M |
| Long-Term Investments | 0 |
| PP&E | 22.5 M |
| Other Non-Current Assets | 153 M |
| Current Liabilities | 156 M |
| Accounts Payable | 1.36 M |
| Short-Term Debt | 2.21 M |
| Other Current Liabilities | 153 M |
| Non-Current Liabilities | 25.4 M |
| Long-Term Debt | 10.2 M |
| Other Non-Current Liabilities | 15.2 M |
EFFICIENCY
Earnings Waterfall
Doximity, Inc.
| Revenue | 570 M |
| Cost Of Revenue | 55.9 M |
| Gross Profit | 515 M |
| Operating Expenses | 284 M |
| Operating Income | 228 M |
| Other Expenses | 4.62 M |
| Net Income | 223 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Doximity, Inc.
| Net Income | 223 M |
| Depreciation & Amortization | -996 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 72.4 M |
| Change in Working Capital | 0 |
| Others | 0 |
| Free Cash Flow | 273 M |
Wall Street Analysts Price Targets
Doximity, Inc.
Wall Street analysts predict an average 1-year price target for DOCS of $52.9 , with forecasts ranging from
a
low of
$38 to a high of $70 .
DOCS Lowest Price Target
Wall Street Target
38 USD
-33.75%
DOCS Average Price Target
Wall Street Target
52.9 USD
-7.85%
DOCS Highest Price Target
Wall Street Target
70 USD
22.04%
4. DIVIDEND
ANALYSIS
DOCS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Doximity, Inc.
Sold
0-3 MONTHS
6.7 M USD 3
3-6 MONTHS
87.6 M USD 6
6-9 MONTHS
6.9 M USD 3
9-12 MONTHS
3.63 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
zacks.com
- 1 day ago
DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health?
DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge.
zacks.com
- 2 days ago
Doximity: A Unique, Debt-Free Healthcare-Tech Platform, Initiate With 'Buy'
I rate Doximity a 'Buy' with a $62 fair value, citing its dominant network among U.S. healthcare professionals and robust growth trajectory. Doximity's strong pharma marketing business, workflow solutions, and AI-driven hiring tools underpin its competitive advantage and long-term expansion potential. The company's debt-free balance sheet, high free cash flow, and substantial share repurchases support its financial health and margin expansion outlook.
seekingalpha.com
- 3 days ago
OGN or DOCS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
zacks.com
- 4 days ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
globenewswire.com
- 1 week ago
DOCS Boosts Client Retention via Workflow Integration and AI Tools
Doximity strengthens client loyalty by embedding AI tools and clinical workflows into its platform for medical professionals.
zacks.com
- 1 week ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
NEW YORK , June 9, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Doximity caused the company to misrepresent or fail to disclose material information concerning the Company's business and operations.
prnewswire.com
- 1 week ago
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
globenewswire.com
- 2 weeks ago
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
Over the past month, Doximity's DOCS shares have lost approximately 4.4% despite the company reporting solid fourth-quarter fiscal 2025 results with $138.3 million in revenues and a 50% adjusted EBITDA margin. For fiscal 2025, revenues totaled $570.4 million, up 20% year over year, with adjusted EBITDA rising 36% to $313.8 million and margin expanding to 55%.
zacks.com
- 2 weeks ago
Dr Martens surges 23% as investors lace up for recovery story
Shares in Dr Martens PLC (LSE:DOCS) jumped 23% on Thursday after the bootmaker delivered a better-than-expected full-year update and signalled a shift towards stabilisation and future growth, giving investors reason to believe the worst may be behind it. The British brand, known for its chunky leather boots, reported adjusted pre-tax profits of £34.1 million for the year to March, around £2 million ahead of consensus and squarely in line with Peel Hunt's forecast.
proactiveinvestors.co.uk
- 2 weeks ago
Dr Martens marketing 'reset' saw annual revenue and profit retreat, eyes return to growth this year
Dr Martens PLC (LSE:DOCS) reported a 10% drop in group revenue to £787.6 million for the year ended 30 March 2025, amidst a marketing 'reset'. Adjusted profit before tax fell to £34.1 million from £97.2 million, the boot brand said in the results statement.
proactiveinvestors.co.uk
- 2 weeks ago
The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks
His concentrated portfolio strategy, focusing on high-quality, long-term holdings, reflects a disciplined, tech-heavy investment approach.
247wallst.com
- 2 weeks ago
8. Profile
Summary
Doximity, Inc. DOCS
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 10.8 B
Dividend Yield
0.00%
Description
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Contact
500, 3rd Street, San Francisco, CA, 94107
https://www.doximity.com
IPO
Date
June 24, 2021
Employees
827
Officers
Mr. Jeffrey A. Tangney
Co-Founder, Chief Executive Officer & Chairperson
Mr. Jey Balachandran
Chief Technology Officer
Dr. Nate Gross M.D.
Co-Founder & Chief Strategy Officer
Ms. Shari Buck
Co-founder and SVice President People & Ops
Mr. Perry Scott Gold
Head of Investor Relations
Mr. Bruno Miranda
Senior Vice President of Engineering
Ms. Anna Bryson
Chief Financial Officer
Ms. Jennifer W. Chaloemtiarana J.D.
General Counsel & Corporate Secretary
Mr. Craig A. Overpeck
Senior Vice President of Commercial Operations
Mr. Joel Davis
Senior Vice President of Product